O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS
Luis Antonio Díaz,Sergio García,Rayan Khan,Gustavo Ayares,Javier Uribe,Francisco Idalsoaga,José Miguel Fuentealba,Eduardo Fuentes,Katherine Maldonado,Mariana Lazo,Catterina Ferreccio,Manuel Mendizabal,Melisa Dirchwolf,Patricia Guerra,Claudia P. Oliveira,Mario Guimarães,Mario Reis,Giada Sebastiani,Mayur Brahmania,Alnoor Ramji,Mina Niazi,Hin Hin Ko,Jordan Feld,Juan Carlos Restrepo,Wagner Ramírez,Omar Alfaro,Marlen Castellanos-Fernández,Enrique Carrera,José Roberto Aguirre Ayala,Abel Sánchez,Marco Sánchez,María Teresa Andara,Graciela Castro,Norberto Chavez-Tapia,Nahum Mendez-Sanchez,Enrique Adames,Julissa Lombardo,Marcos Girala,Elías Morán,Martin Padilla-Machaca,Javier Díaz,Martín Tagle,Victoria Mainardi,Nelia Hernandez,Edmundo Martínez,Edilmar Alvarado-Tapias,Roberto Leon,Andrew Talal,Emmanuel Thomas,Sandra Springer,Mauricio Garcia-Saenz-de-Sicilia,Wei Zhang,Jasmohan Bajaj,Elliot B. Tapper,Manhal J. Izzy,Robert G. Gish,Bashar Attar,Thomas G. Cotter,Michael R. Lucey,Patrick S. Kamath,Ashwani K. Singal,Ramón Bataller,Gabriel Mezzano,Alejandro Soza,Jeffrey V. Lazarus,Marco Arrese,Juan Pablo Arab
DOI: https://doi.org/10.1016/j.aohep.2023.101273
IF: 3.388
2024-02-01
Annals of Hepatology
Abstract:Introduction and Objectives Although the WHO strategy aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030, national strategies are variable worldwide. This study aimed to assess the establishment of different policies and strategies to eliminate HCV in the Americas. Materials and Methods We conducted a 23-item survey about HCV-related policies and strategies among gastroenterologists and hepatologists in the Americas. The survey was carried out electronically (2022–2023). Data were compared with governmental institutions, regulatory agencies, scientific societies, and scientific publications. We estimated an index obtained from a regression scoring method through exploratory analysis, and row values were normalized from 0 to 100. Results We obtained 52 responses from 19 countries. The median HCV-related policies index was 51.4 [IQR:27.3–70.1]. The lower establishment of HCV-related policies was observed in Ecuador (0.0), Honduras (6.6), and Costa Rica (9.8), while the highest performance was observed in Argentina (94.1), Colombia (94.7), and Canada (100)(Figure 1A). Fifteen (78.9%) countries have adopted a national strategic plan to eliminate HCV. Three (15.8%) countries have universal screening for HCV infection (Figure 1B). After a positive HCV serological test, 10 (52.6%) countries perform reflex testing to confirm HCV diagnosis using the same sample. However, only 7 (36.8%) countries have an alert system for the requesting physician. Twelve (63.2%) countries have a direct referral system for specialized care of HCV-positive cases. Universal access to direct-acting antivirals (DAAs) exists in 15 (78.9%) countries. Universal access to DAAs was not widely available in Cuba, Ecuador, Venezuela, and the United States. Seven (36.8%) countries have generic DAAs available. Only 3 (15.8%) countries performed a retrospective search for HCV-positive cases that could have been lost to follow-up. Conclusions Although most countries have adopted a national strategic plan to eliminate HCV, there are several issues and barriers to elimination in the Americas.
gastroenterology & hepatology